MED-OLMESARTAN TABLET

Šalis: Kanada

kalba: anglų

Šaltinis: Health Canada

Veiklioji medžiaga:

OLMESARTAN MEDOXOMIL

Prieinama:

GENERIC MEDICAL PARTNERS INC

ATC kodas:

C09CA08

INN (Tarptautinis Pavadinimas):

OLMESARTAN MEDOXOMIL

Dozė:

40MG

Vaisto forma:

TABLET

Sudėtis:

OLMESARTAN MEDOXOMIL 40MG

Vartojimo būdas:

ORAL

Vienetai pakuotėje:

2X14/100

Recepto tipas:

Prescription

Gydymo sritis:

ANGIOTENSIN II RECEPTOR ANTAGONISTS

Produkto santrauka:

Active ingredient group (AIG) number: 0152496003; AHFS:

Autorizacija statusas:

APPROVED

Leidimo data:

2017-05-01

Prekės savybės

_Page 1 of 27_
PRODUCT MONOGRAPH
PR
MED-OLMESARTAN
Olmesartan Medoxomil Tablets
20 mg, and 40 mg olmesartan medoxomil,
Angiotensin II AT
1
Receptor
Blocker
GENERIC MEDICAL PARTNERS INC.
251 Consumers Road, Suite 1200
Toronto, Ontario
M2J 4R3
Date of Revision:
APRIL 24, 2017
Submission Control No: 178734, 204768
_Page 2 of 27_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
........................................................ 3
SUMMARY PRODUCT INFORMATION
.......................................................................
3
INDICATIONS AND CLINICAL USE
.............................................................................
3
CONTRAINDICATIONS
.................................................................................................
4
WARNINGS AND PRECAUTIONS
.................................................................................
4
ADVERSE REACTIONS
...................................................................................................
8
DRUG INTERACTIONS
...................................................................................................
10
DOSAGE AND ADMINISTRATION
...............................................................................
12
OVERDOSAGE
.................................................................................................................
14
ACTION AND CLINICAL PHARMACOLOGY
............................................................. 14
STORAGE AND STABILITY
..........................................................................................
16
DOSAGE FORMS, COMPOSITION AND PACKAGING
.............................................. 16
PART II: SCIENTIFIC INFORMATION
................................................................................
17
PHARMACEUTICAL INFORMATION
...........................................................................
17
CLINICAL TRIALS
...........................................................................................................
18
DETAILED PHARMACOLOGY
............